Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
Recruiting · NCT07751133 · Registry updated 2026-09-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-04 | NCT07751133 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Research UK | 59 |
| Prostate Cancer UK | 4 |
| University College, London | 222 |
| University of Manchester | 85 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Christie NHS Foundation Trust | Manchester | United Kingdom | 40 |